Kaleido Stock Leadership

KLDO -  USA Stock  

USD 5.78  0.11  1.94%

Kaleido Biosciences employes about 82 people. The company is managed by 12 executives with total tenure of roughly 17 years, averaging almost 1.0 years of service per executive having 6.83 employees per reported executive. Inspection of Kaleido Biosciences management performance can provide insight into the company performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Kaleido Biosciences future performance.
Please see Stocks Correlation.

Search Insiders 

 
Refresh
  Mike Bonney  Chairman
Chairman of the Board, CEO
  Geoffrey Maltzahn  President
President Co-Founder
  Jeremy Buzzard  President
Senior Vice President - Corporate Development

Kaleido Biosciences Management Team Effectiveness

Kaleido Biosciences has return on total asset (ROA) of (59.77) % which means that it has lost $59.77 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (161.51) %, meaning that it created substantial loss on money invested by shareholders. Kaleido Biosciences management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return on Average Assets is estimated to slide to -1.23. The value of Return on Average Equity is estimated to slide to -2.37. Kaleido Biosciences Total Assets are quite stable at the moment as compared to the past year. The company's current value of Total Assets is estimated at 68.54 Million. Current Assets is expected to rise to about 58.5 M this year, although the value of Assets Non Current will most likely fall to about 10.1 M.

Kaleido Biosciences Quarterly Total Assets

105.03 MillionShare
The value of Weighted Average Shares is estimated to slide to about 27.6 M. The value of Weighted Average Shares Diluted is expected to slide to about 27.6 M

Kaleido Biosciences Workforce Comparison

Kaleido Biosciences is currently regarded as number one stock in number of employees category among related companies. The total workforce of Biotechnology industry is now estimated at about 339. Kaleido Biosciences totals roughly 82.0 in number of employees claiming about 24% of stocks in Biotechnology industry.

Kaleido Biosciences Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Kaleido Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Kaleido Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Kaleido Biosciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Kaleido Biosciences Benchmark Summation

Kaleido Biosciences Notable Stakeholders

A Kaleido Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Kaleido Biosciences often face trade-offs trying to please all of them. Kaleido Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Kaleido Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Mike Bonney - Chairman of the Board, CEOProfile
Geoffrey Maltzahn - President Co-FounderProfile
Jeremy Buzzard - Senior Vice President - Corporate DevelopmentProfile
Jeffery Moore - Senior Vice President - Finance & AdministrationProfile
Grady Burnett - DirectorProfile
Bonnie Bassler - DirectorProfile
John Sculley - DirectorProfile
Theo MelasKyriazi - Independent DirectorProfile
Johannes Vlieg - Chief Scientific OfficerProfile
Jerald Korn - General Counsel, Corporate SecretaryProfile
Ruth ThieroffEkerdt - Chief Medical OfficerProfile
Clare Fisher - Chief Business OfficerProfile

About Kaleido Biosciences Management Performance

The success or failure of an entity such as Kaleido Biosciences often depends on how effective the management is. Kaleido Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Kaleido management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Kaleido management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please read more on our stock advisor page.
Last ReportedProjected for 2021
Return on Average Assets(1.14) (1.23) 
Return on Average Equity(2.31) (2.37) 
Return on Invested Capital(3.77) (4.07) 
Return on Sales(72.76) (78.50) 
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Kaleido Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 82 people.
The data published in Kaleido Biosciences' official financial statements usually reflect Kaleido Biosciences' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Kaleido Biosciences. For example, before you start analyzing numbers published by Kaleido accountants, it's critical to develop an understanding of what Kaleido Biosciences' liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Kaleido Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Kaleido Biosciences' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Kaleido Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Kaleido Biosciences. Please utilize our Beneish M Score to check the likelihood of Kaleido Biosciences' management to manipulate its earnings.

Kaleido Biosciences Workforce Analysis

Traditionally, organizations such as Kaleido Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Kaleido Biosciences within its industry.

Kaleido Biosciences Manpower Efficiency

Return on Kaleido Biosciences Manpower

Revenue Per Employee15.5 K
Revenue Per Executive105.8 K
Net Loss Per Employee1 M
Net Loss Per Executive7.1 M
Working Capital Per Employee762.7 K
Working Capital Per Executive5.2 M
Please see Stocks Correlation. Note that the Kaleido Biosciences information on this page should be used as a complementary analysis to other Kaleido Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Money Managers module to screen money managers from public funds and ETFs managed around the world.

Complementary Tools for Kaleido Stock analysis

When running Kaleido Biosciences price analysis, check to measure Kaleido Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kaleido Biosciences is operating at the current time. Most of Kaleido Biosciences' value examination focuses on studying past and present price action to predict the probability of Kaleido Biosciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kaleido Biosciences' price. Additionally, you may evaluate how the addition of Kaleido Biosciences to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
The market value of Kaleido Biosciences is measured differently than its book value, which is the value of Kaleido that is recorded on the company's balance sheet. Investors also form their own opinion of Kaleido Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Kaleido Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kaleido Biosciences' market value can be influenced by many factors that don't directly affect Kaleido Biosciences underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kaleido Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Kaleido Biosciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kaleido Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.